Dejaco, Christian
Brouwer, Elisabeth
Mason, Justin C.
Buttgereit, Frank
Matteson, Eric L.
Dasgupta, Bhaskar
Article History
First Online: 14 September 2017
Competing interests
: C.D. declares that he has received consultancy fees and honoraria from AbbVie, Celgene, Lilly, Merck, MSD, Novartis, Pfizer, Roche, Sandoz and UCB, and unrestricted grant support from MSD and Pfizer, and has acted as a consultant and advisory board member for GSK. E.B. declares that she has received consultancy fees from Roche and an unrestricted grant from Janssen. J.M. declares that he has received consultancy fees and honoraria from Novartis and Roche. F.B. declares that he has received consultancy fees, honoraria and travel expenses from Galapagos, Horizon Pharma (formerly Nitec Pharma), Mundipharma and Roche and grant support from Horizon Pharma, and that he has served as co-principal investigator and site investigator in a Mundipharma-sponsored trial in PMR investigating the effects of modified-release prednisone. E.L.M. declares that he has served as coordinating investigator in a Novartis-sponsored PRM trial, as a consultant in a GSK-sponsored PMR trial, as a consultant for Endocyte and GSK and as a site investigator in GCA trials sponsored by Bristol Meyer Squibb, Genentech, GSK and Hoffman-LaRoche, and that he is an author and editor for UpToDate and Paradigm. B.D. declares that he has acted as a consultant and advisory board member for GSK, Merck, Mundipharma, Pfizer, Roche, Servier and Sobi) and that he has received unrestricted grant support from Napp and Roche and honoraria from Merck and UCB.